Condition
Chemoembolization, Therapeutic
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Completed2
Unknown1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07561983Phase 2Not Yet Recruiting
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
NCT02435953Phase 3Completed
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma
NCT02764801Phase 3Completed
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
NCT03283956Unknown
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
Showing all 4 trials